

Second-Quarter

# 2024 Financial Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Demonstrated strong business momentum



Achieved regulatory and clinical milestones



Expanded and diversified pipeline



“Our business is demonstrating strong momentum as we exit the first half of the year. Through excellent scientific, commercial and operational execution, we’re achieving significant milestones for our company and for patients. I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as we continue delivering innovation that solves unmet medical needs.”

Rob Davis  
Chairman and Chief Executive Officer, Merck

NYSE: MRK

WORLDWIDE SALES

GAAP EPS

NON-GAAP EPS<sup>1</sup>

Q2 performance reflects continued growth

\$16.1B

\$2.14

\$2.28

Updated ranges for 2024 financial outlook

\$63.4B  
to  
\$64.4B

\$7.94  
to  
\$8.04

Sales

**KEYTRUDA**  
(pembrolizumab) injection 100mg

\$7.3B  
16% Growth


**GARDASIL**  
(Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant)

**GARDASIL.9**  
Human Papillomavirus 9-valent Vaccine, Recombinant

\$2.5B  
1% Growth

**MERCK**  
Animal Health

\$1.5B  
2% Growth



# Q2

2024  
Financial Results

<sup>1</sup> A reconciliation of GAAP to non-GAAP EPS can be found in the company’s earnings release.